NCT02339168View on ClinicalTrials.gov

Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 22, 2016

Primary Completion Date

October 15, 2024

Study Completion Date

February 24, 2025

Conditions
Prostate Cancer
Interventions
DRUG

Enzalutamide

Given PO

DRUG

Metformin Hydrochloride

Given PO

Trial Locations (1)

95817

University of California Davis Comprehensive Cancer Center, Sacramento

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Medivation, Inc.

INDUSTRY

collaborator

Astellas Pharma Inc

INDUSTRY

lead

University of California, Davis

OTHER